Prospective Registration of Head and Neck Cancer

Summary

Head and neck cancers account for the sixth leading cause of cancers worldwide. The annual incidence of Head and neck cancers is more than 650,000 the patients each year. Head and neck cancers are associated with smoking, alcohol consumption, human papilloma virus (type 16 and 18) and previous exposure to radiation.

So far, most of clinical and research data about head and neck cancers, such as the etiology, pathogenesis, prognosis factors and associated factors, treatment outcomes, are from Western countries. However, due to various environmental factors, for example race, genetics, geographical factors, general hygiene and health care system differences, the possibility of differences of disease characteristics between Western and Asian people should be considered.

For several decades, there have been many studies about treatment modalities (surgery, chemotherapy, and radiation therapy), complications and side effects for head and neck cancers in the West. Many institutions tried to improve the survival rate and resolve the toxicity of chemotherapy and radiation treatment for head and neck cancer patients. However there has been little information about the characteristics of head and neck cancers, effectiveness of treatment (survival rate, recurrence, and complication rate), and prognosis, particularly in Korean as well as in Asian patients.

Therefore it is necessary to evaluate and analyze the features of head and neck cancers such as etiology, pathogenesis, risk factors, prognostic factors, treatment outcomes in a site specific cohort (South Korea) separately. It could be helpful to improve the treatment outcomes of head and neck cancers overall, to design race or site specific treatments for head and neck cancers, and to develop management strategy common in Asia as well as the West.

The purpose of this study is

1. To establish the prospective tumor registry about patient's information, treatment-related morbidities, treatment outcomes and quality of life, in addition to the prospective collection of patient samples (blood and tumor tissues).
2. To establish the predictive model for treatment outcomes and treatment-related morbidities.
3. To develop the biomarkers as predictive and/or prognostic factors.

Conditions

• Head and Neck Cancer

Interventions

OTHER

chart review

The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival. Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time.

Sponsors & Collaborators

• Samsung Medical Center

  lead OTHER

Principal Investigators

• Han-Sin Jeong, M.D.Ph.D. · Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Se-Hoon Lee, M.D.Ph.D. · Department of Hemato-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Dongryul Oh, M.D.Ph.D. · Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Chung-Hwan Baek, M.D.Ph.D. · Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Young-Ik Son, M.D.Ph.D. · Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Man Ki Chung, M.D.Ph.D. · Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Young Chan Ahn, M.D.Ph.D. · Department of Radiation Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Myung-Ju Ahn, M.D.Ph.D. · Department of Hemato-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center

• Keunchil Park, M.D.Ph.D. · Department of Hemato-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center

Eligibility

Min Age

19 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-09-01

Primary Completion

2024-12-31

Completion

2024-12-31

Countries

• South Korea

Study Locations